Journal ArticleDOI
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Geoffrey Chupp,Eric S. Bradford,Frank C. Albers,Daniel J. Bratton,Jie Wang-Jairaj,Linda M. Nelsen,Jennifer Trevor,Antoine Magnan,Anneke ten Brinke +8 more
TLDR
Mepolizumab was associated with significant improvements in HRQOL in patients with severe eosinophilic asthma, and had a safety profile similar to that of placebo, and these results add to and support the use of mepolizumAB as a favourable add-on treatment option to standard of care.Citations
More filters
Journal ArticleDOI
Type 2 immunity in tissue repair and fibrosis
TL;DR: The mechanisms by which type 2 immunity contributes to tissue regeneration and fibrosis following injury are discussed.
Journal ArticleDOI
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.
Ian D. Pavord,Pascal Chanez,Gerard J. Criner,Huib A. M. Kerstjens,Stephanie Korn,Njira L Lugogo,J.-B. Jean-Benoit Martinot,Hironori Sagara,Frank Albers,Eric S. Bradford,Stephanie Harris,Bhabita Mayer,Bhabita Mayer,David Rubin,Steven W. Yancey,Frank C. Sciurba +15 more
TL;DR: Mepolizumab at a dose of 100 mg was associated with a lower annual rate of moderate or severe exacerbations than placebo among patients with COPD and an eosinophilic phenotype, which suggests that eos inophilic airway inflammation contributes to COPD exacerbations.
Journal ArticleDOI
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline
Fernando Holguin,Juan Carlos Cardet,Kian Fan Chung,Sarah Diver,Diogenes S. Ferreira,Diogenes S. Ferreira,Anne M. Fitzpatrick,Mina Gaga,Liz Kellermeyer,Sandhya Khurana,Shandra L Knight,Vanessa M. McDonald,Rebecca L. Morgan,Victor E. Ortega,David Rigau,Padmaja Subbarao,Thomy Tonia,Ian M. Adcock,Eugene R. Bleecker,Christopher E. Brightling,Louis-Philippe Boulet,Michael D. Cabana,Mario Castro,Pascal Chanez,Adnan Custovic,Ratko Djukanovic,Urs Frey,Betty Frankemölle,Peter G. Gibson,Dominique Hamerlijnck,Nizar N. Jarjour,Satoshi Konno,Huahao Shen,Cathy Vitary,Andrew Bush +34 more
TL;DR: Clinical recommendations for the management of severe asthma are provided and the use of novel therapies for severe asthma, specifically biologicals for type 2 high asthma, and antimuscarinic agents and macrolides, as well as on biomarkers for predicting treatment response are made.
Journal ArticleDOI
Anti‐IL5 therapies for asthma
TL;DR: To compare the effects of therapies targeting IL-5 signalling with placebo on exacerbations, health-related qualify of life (HRQoL) measures, and lung function in adults and children with chronic asthma, a first update of a previously published review in The Cochrane Library is published.
Journal ArticleDOI
Role of Biologics in Asthma.
TL;DR: The mechanism of action, indications, expected benefits, and side effects of each of the currently approved biologics for severe uncontrolled asthma are reviewed and promising therapeutic targets for the future are discussed.
References
More filters
Journal ArticleDOI
A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.
TL;DR: The St. George's Respiratory Questionnaire is a valid measure of impaired health in diseases of chronic airflow limitation that is repeatable and sensitive andMultivariate analysis demonstrated that SGRQ scores summed a number of areas of disease activity.
Journal ArticleDOI
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung,Sally E. Wenzel,Jan Brozek,Andrew Bush,Mario Castro,Peter J. Sterk,Ian M. Adcock,Eric D. Bateman,Elisabeth H. Bel,Eugene R. Bleecker,Louis-Philippe Boulet,Christopher E. Brightling,Pascal Chanez,Sven-Erik Dahlén,Ratko Djukanovic,Urs Frey,Mina Gaga,Peter G. Gibson,Qutayba Hamid,Nizar N. Jajour,Thais Mauad,Ronald L. Sorkness,W. Gerald Teague +22 more
TL;DR: Recommendations and guidelines on the evaluation and treatment of severe asthma in children and adults and coordinated research efforts for improved phenotyping will provide safe and effective biomarker-driven approaches to severe asthma therapy are provided.
Journal ArticleDOI
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Ian D. Pavord,Stephanie Korn,Peter H. Howarth,Eugene R. Bleecker,Roland Buhl,Oliver N. Keene,Hector Ortega,Pascal Chanez +7 more
TL;DR: Mepolizumab is an effective and well tolerated treatment that reduces the risk of asthma exacerbations in patients with severe eosinophilic asthma.
Journal ArticleDOI
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector Ortega,Mark C. Liu,Ian D. Pavord,Guy Brusselle,J. Mark FitzGerald,Alfredo Chetta,Marc Humbert,Lynn Katz,Oliver N. Keene,Steven W. Yancey,Pascal Chanez +10 more
TL;DR: Mepolizumab administered either intravenously or subcutaneously significantly reduced asthma exacerbations and was associated with improvements in markers of asthma control and the safety profile of mepolIZumab was similar to that of placebo.
Related Papers (5)
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung,Sally E. Wenzel,Jan Brozek,Andrew Bush,Mario Castro,Peter J. Sterk,Ian M. Adcock,Eric D. Bateman,Elisabeth H. Bel,Eugene R. Bleecker,Louis-Philippe Boulet,Christopher E. Brightling,Pascal Chanez,Sven-Erik Dahlén,Ratko Djukanovic,Urs Frey,Mina Gaga,Peter G. Gibson,Qutayba Hamid,Nizar N. Jajour,Thais Mauad,Ronald L. Sorkness,W. Gerald Teague +22 more